Ertugliflozin in the treatment of type 2 diabetes mellitus

Ertugliflozin in the treatment of type 2 diabetes mellitus

More than 422 million people worldwide have diabetes, with 90–95% having type 2 diabetes (T2D). Glycemic control of T2D has demonstrated reductions in microvascular complications but recent data have demonstrated improvements in macrovascular outcomes with sodium–glucose cotransporter 2 (SGLT2) inhi...

Full description

Bibliographic Details
Main Authors: Joel C Marrs, Sarah L Anderson
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-11-01
Series:Drugs in Context
Subjects:
adverse effects
blood pressure
body weight
ertugliflozin
diabetes mellitus
drug interactions
metabolic effects
sodium–glucose cotransporter 2 inhibitors
Online Access:https://www.drugsincontext.com/ertugliflozin-in-the-treatment-of-type-2-diabetes-mellitus

Internet

https://www.drugsincontext.com/ertugliflozin-in-the-treatment-of-type-2-diabetes-mellitus

Similar Items